Literature DB >> 28940257

Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.

Xu-Feng Zhang1,2, Eliza W Beal2, Matthew Weiss3, Luca Aldrighetti4, George A Poultsides5, Todd W Bauer6, Ryan C Fields7, Shishir K Maithel8, Hugo P Marques9, Timothy M Pawlik2.   

Abstract

BACKGROUND AND OBJECTIVES: The objective of the study was to evaluate the impact of timing of disease occurrence and hepatic resection on long-term outcome of neuroendocrine liver metastasis (NELM).
METHODS: A total of 420 patients undergoing curative-intent resection for NELM were identified from a multi-institutional database. Date of primary resection, NELM detection and resection, intraoperative details, disease-specific (DSS), and recurrence-free survival (RFS) were obtained.
RESULTS: A total of 243 (57.9%) patients had synchronous NELM, while 177 (42.1%) developed metachronous NELM. On propensity score matching (PSM), patients with synchronous versus metachronous NELM had comparable DSS (10-year DSS, 76.2% vs 85.9%, P = 0.105), yet a worse RFS (10-year RFS, 34.1% vs 59.8%, P = 0.008). DSS and RFS were comparable regardless of operative approach (simultaneous vs staged, both P > 0.1). Among patients who developed metachronous NELM, no difference in long-term outcomes were identified between early (≤2 years, n = 102, 57.6%) and late (>2 years, n = 68, 42.4%) disease on PSM (both P > 0.1).
CONCLUSIONS: Patients with synchronous NELM had a higher risk of tumor recurrence after hepatic resection versus patients with metachronous disease. The time to development of metachronous NELM did not affect long-term outcome. Curative-intent hepatic resection should be considered for patients who develop NELM regardless of the timing of disease presentation.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  metachronous; neuroendocrine liver metastasis; synchronous

Mesh:

Year:  2017        PMID: 28940257     DOI: 10.1002/jso.24832

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Is chronological age really not a contraindication to gastrectomy for very elderly patients?

Authors:  Jiong-Jie Yu; Li-Yang Sun; Tian Yang
Journal:  Surg Today       Date:  2018-05-17       Impact factor: 2.549

Review 2.  Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors:  Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

Review 3.  [Liver metastases of neuroendocrine tumors].

Authors:  S Nadalin; M Peters; A Königsrainer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-17

4.  Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.

Authors:  Shinsei Yumoto; Shigeki Nakagawa; Hiromitsu Hayashi; Daisuke Ogawa; Yuta Shiraishi; Hiroki Sato; Takashi Matsumoto; Katsunori Imai; Yo-Ichi Yamashita; Hideo Baba
Journal:  Clin J Gastroenterol       Date:  2022-08-29

5.  Microwave ablation combined with hepatectomy for treatment of neuroendocrine tumor liver metastases.

Authors:  Jin-Zhu Zhang; Shu Li; Wei-Hua Zhu; Da-Fang Zhang
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

6.  Is Long-Term Survival in Metastases from Neuroendocrine Neoplasms Improved by Liver Resection?

Authors:  Alin Kraft; Adina Croitoru; Cosmin Moldovan; Ioana Lupescu; Dana Tomescu; Raluca Purnichescu-Purtan; Vlad Herlea; Irinel Popescu; Florin Botea
Journal:  Medicina (Kaunas)       Date:  2021-12-23       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.